(BIOA) (BIOA) Stock Price, News & Analysis

Company Overview

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Key Stats

• Today's Range: $4.40 to $5.00
• 50-Day Range: N/A
• 52-Week Range: $2.88 to $26.62
• Volume: 512,188 shs
• Average Volume: 471,583 shs
• Market Capitalization: $144.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.67
• Consensus Rating: Reduce

BIOA Stock Analysis - Frequently Asked Questions

How were (BIOA)'s earnings last quarter?

(BIOA) (NYSE:BIOA) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($6.70) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $6.08.

When did (BIOA) IPO?

(BIOA) (BIOA) raised $198 million in an initial public offering (IPO) on Thursday, September 26th 2024. The company issued 11,000,000 shares at $18.00 per share.

Who are (BIOA)'s major shareholders?

(BIOA)'s top institutional investors include RA Capital Management L.P. (2.94%), ADAR1 Capital Management LLC (2.71%), Siren L.L.C. (1.07%) and Simplex Trading LLC. Insiders that own company stock include Vijay Satyanand Pande and Shane Barton.
View institutional ownership trends.

What other stocks do shareholders of (BIOA) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), NVIDIA (NVDA) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:BIOA
• CIK: 1534287
• Web: www.bio-amber.com
• Phone: +1-612-7474423
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.67
• High Stock Price Target: $7.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +42.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,850,000
• Free Float: N/A
• Market Cap: $142.86 million
• Optionable: Not Optionable
• Beta: N/A